What is the composition of Butalbital (barbiturate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Composition of Butalbital

Butalbital is a short- to intermediate-acting barbiturate (5-allyl-5-isobutylbarbituric acid) that is never prescribed alone but only available in combination products, most commonly with acetaminophen (325 mg), caffeine (40 mg), and sometimes aspirin or codeine. 1

Chemical Structure and Properties

  • Butalbital itself is a white, odorless, slightly bitter crystalline powder with the chemical name 5-allyl-5-isobutylbarbituric acid and a molecular weight of approximately 220-232 Da 2, 1
  • The standard formulation contains 50 mg of butalbital per capsule or tablet, which carries a warning that it "may be habit-forming" 1

Common Combination Products

The typical butalbital-containing product includes three active ingredients 1:

  • Butalbital 50 mg (the barbiturate component)
  • Acetaminophen 325 mg (the analgesic/antipyretic component)
  • Caffeine 40 mg (the CNS stimulant component)

Alternative formulations may substitute aspirin for acetaminophen or add codeine (as in Fiorinal with Codeine) 3

Mechanism of Action

  • Butalbital works via gamma-aminobutyric acid (GABA) receptors in the central nervous system, producing sedation, anxiolytic effects, and hypnotic properties 2, 4
  • The medication is primarily metabolized in the liver through the cytochrome P450 enzyme system and acts as a CYP enzyme inducer, potentially affecting metabolism of other medications 2, 5
  • Approximately 20-25% of long-acting barbiturates are excreted unchanged in urine, though butalbital (as a short-acting agent) has less renal excretion than phenobarbital 2

Pharmacokinetic Properties

  • Protein binding: 26-35% 2, 3
  • Volume of distribution: 0.5-1.0 L/kg 2, 3
  • Elimination half-life: 15-48 hours (short- to intermediate-acting) 2
  • Duration of action: 3-4 hours 2

Critical Safety Profile

Butalbital carries the same clinical risks as Schedule III controlled barbiturates, including habit formation, tolerance, physical dependence, and withdrawal seizures with chronic use 2, 6, 5

Key Clinical Risks:

  • Medication-overuse headache develops when used more than twice weekly, creating a vicious cycle of increasing headache frequency 6, 7
  • Additive CNS and respiratory depression when combined with other depressants (alcohol, opioids, benzodiazepines, anesthetics) can be life-threatening 2, 5
  • Abrupt discontinuation after long-term use can cause intractable seizures, visual/auditory hallucinations, delirium, and potentially fatal withdrawal 2
  • Hepatotoxicity risk from the acetaminophen component when total daily intake exceeds 4000 mg from all sources 6

Prescribing Recommendations

  • Limit use to no more than twice weekly to prevent medication-overuse headache and dependence 6, 5, 7
  • Use only as backup medication when NSAIDs, triptans, and other first-line agents are contraindicated or have failed 6
  • Daily use indicates treatment failure and warrants immediate therapy adjustment 6, 4
  • For perioperative management: ideally wean slowly over 2 weeks prior to surgery; if unable to wean, continue the medication to avoid perioperative withdrawal 2, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Association Between Fioricet and Depression

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Butalbital-Acetaminophen-Caffeine Controlled Substance Classification and Clinical Considerations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Safety of Fioricet and Driving

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.